US-based cancer detection technology developer C2i Genomics has received $100m in convertible note financing from investors including Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities.
The round was led by healthcare-focused investment firm Casdin Capital and also featured NFX, Section 32, iGlobe Partners, Driehaus Capital, Silver Lake, Gordon Asset Management, LionBird, The Mark Foundation for Cancer Research and Duquesne Family Office.
Founded in 2019, C2i Genomics is developing cloud-based software that can detect residual cancer cells in patients following the surgical removal of tumours. It claims its C2-Intelligence Platform can detect the presence of cancer with only two millilitres of a patient’s blood.
The financing was raised across two $50m tranches and will support development and commercialisation activities for the company’s technology platform.
Casdin Capital also led the startup’s $12m series A round in June 2020, with participation from NFX Capital and The Mark Foundation.
C2i Genomics co-founder and CEO Asaf Zviran said: “As a cancer survivor myself, I founded C2i to help patients and physicians navigate the complicated cancer treatment process with better intelligence.
“I am beyond grateful for the backing of this incredible list of investors to help give cancer patients the precision and certainty they expect and deserve.”